Skip to main content

Table 4 Association of biomarkers with odds of having an on or post-study SRE

From: Effects of de-escalated bisphosphonate therapy on bone turnover biomarkers in breast cancer patients with bone metastases

  Baseline Change from Baseline to 12 Weeks
Odds ratio (95% CI) p-value Odds ratio (95% CI) p-value
CTx /10 unit change 1.00 (0.94, 1.07) 0.99 1.04 (0.95, 1.14) 0.39
BSAP /unit change 1.03 (0.97, 1.09) 0.36 0.90 (0.73, 1.11) 0.32
TGF-β /unit change 1.05 (0.90, 1.23) 0.54 0.98 (0.83, 1.16) 0.83
Activin-A /100 unit change 0.98 (0.89, 1.07) 0.60 0.99 (0.93, 1.04) 0.64
NTx /10 unit change 1.00 (0.97, 1.02) 0.69 1.01 (0.97, 1.06) 0.56
P1NP /10000 unit change 0.97 (0.79, 1.18) 0.75 0.98 (0.80, 1.20) 0.84
BSP /10 unit change 1.00 (0.63, 1.60) 0.99 0.94 (0.60, 1.47) 0.79
FACT-BP /unit change 1.13 (1.01, 1.28) 0.041 0.99 (0.87, 1.14) 0.93
BPI /unit change 1.03 (0.99, 1.08) 0.16 1.00 (0.94, 1.06) 0.93
Duration of bone metastases /month 1.03 (0.99, 1.08) 0.14   
Pre-Study SRE Yes versus no 7.50 (0.74, 75.72) 0.088   
Treatment Group 2 versus 1 1.07 (0.18, 6.21) 0.94